

Influence of Choline-Based Ionic Liquids as Neoteric Green Solvents on Aqueous Solubility of Lamotrigine and Piroxicam Drugs

Hemayat Shekaari^{1*}, Negar Basteholia¹, Masumeh Mokhtarpour¹, Mohammed Taghi Zafarani-Moattar¹

¹Department of Physical Chemistry, University of Tabriz, Tabriz, Iran.

Article Info

Article History:

Received: 10 December 2021

Accepted: 28 February 2022

ePublished: 14 March 2022

Keywords:

- Activity coefficient models
- Choline-based ionic liquids
- Lamotrigine
- Piroxicam
- Solubility

Abstract

Background: New compounds called choline-based ionic liquids (ILs) that are environmentally friendly have become more attractive. In this study, some choline-based ILs (choline lactate (ChLa) and choline propionate (ChPro)) have been used to increase the aqueous solubility of lamotrigine (LTG) and piroxicam (PXM) at $T = 298.15$ to 313.15 K.

Methods: ILs were prepared and purified. The solubility of drugs in the aqueous ILs solutions was measured at different temperatures with shake flask method.

Results: The solubility of the investigated drugs increased with increasing the weight fraction of ILs. The solubility data were correlated by e-NRTL, Wilson, Apelblat and λh (Buchowski) models.

Conclusion: The aqueous solubility of drugs depends on both the weight fraction of co-solvents and the solution temperature. These two essential parameters were analyzed through some semi-empirical and activity coefficient models getting the average relative deviation percent as e-NRTL (3.09%) < Wilson (3.92%) (for full range concentration of co-solvent) and Apelblat (3.52%) < λh (Buchowski) (5.11%) (for the dilute region of co-solvent). In addition, the results show that the aqueous solubility increases with rising temperature and there are strong interactions between the drug and the ILs.

Introduction

Piroxicam (PXM, 4-hydroxy-2-methyl-N-(pyridine-2-yl)-2H-1, 2-benzo-thiazine-3-carboxamide-1, 2-dioxide) is a chemically different potent drug with a long half-life which makes it suitable to use once a day. In addition, it is a member of oxicams that can treat rheumatoid arthritis and osteoarthritis. So, it can be concluded that the application of PXM is in musculoskeletal and joint disorders.^{1,2} The mentioned drug is a sub-branch of non-steroidal anti-inflammatory drugs (NSAIDs).³ Moreover, this poorly soluble, highly permeable drug be a suitable alternative to aspirin, indomethacin, naproxen, ibuprofen, ketoprofen, sulindac, phenylbutazone, and diclofenac in the treatment of rheumatic diseases. The solubility of a drug is significant in the pharmaceutical industry because the amount of medicine absorbed by the body depends on its solubility in water.⁴ The second drug used in this research is lamotrigine (LTG). The LTG, 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, is an antiepileptic agent for monotherapy and as an adjunct in treatment with other antiepileptic agents for partial seizures.⁵ To enhance the usage of these compounds, it is necessary to examine the procedure for increasing the aqueous solubility of the mentioned drugs. The co-solvency method, addition of surface-

active agents, salt formation, complexation, hydrotropism, crystal engineering, preparation of soluble pro-drug, and more recently, the addition of ionic liquids (ILs) are the methods that can increase the solubility of drugs in water, consequently the usage of them.^{6,7} Paul Walden performed the first IL study in 1914 on the physical properties of ethyl ammonium nitrate [EtNH₃⁺] [NO₃⁻]. In recent years, ILs have been emerged as novel solvents in a wide range of areas due to their specific properties. In other words, ILs are organic salts and can be categorized in green solvents because they are near non-volatile. They also have a low melting point and dissolve a wide range of components.⁸ These novel and green solvents are also named designer solvents. Their physicochemical properties which can be changed by choosing suitable cation and anion. The choline 2-hydroxy-N, N, N-trimethylethanaminium (or 2-hydroxyethyl-trimethyl-ammonium) quaternary ammonium cations that couple with lots of anions like chloride, iodide, acetate, hydroxide, tartrate, etc.⁹ The ILs that contain choline are considered choline-based ILs. These classes of ILs are non-toxic, environmental, low-cost, and water-soluble, so they are famous among the various kinds of ILs.¹⁰ The ILs can be used as solubility enhancers, permeability enhancers, drug-ILs, protein stabilizers, etc.¹¹

*Corresponding Author: Hemayat Shekaari, E-mail: hemayatt@yahoo.com

©2022 The Author(s). This is an open access article and applies the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>). Non-commercial uses of the work are permitted, provided the original work is properly cited.




Figure 1. Stages of ChLa synthesis.

In this work, we measured the solubility of LTG and PXM in choline-based ILs at different weight fractions at temperatures $T = (298.15 \text{ to } 313.15) \text{ K}$. For correlation between LTG and PXM experimental data in the dilute region of the ILs mass fraction from the semi-experimental models of Apelblat and λh and in the concentrated area of the co-solvent, the local composition models Wilson and e- NRTL were used. Finally, to minimize the cost of the measurement process, the used ILs were recovered.

Materials and Methods

Chemicals

Lamotrigine and piroxicam were employed by the Zahravi pharmaceutical company (Tabriz, Iran). The detailed information about all materials is listed in Table 1.

Synthesis of ILs

The ILs were prepared as follows: the reaction was conducted by slow addition of an aqueous solution of choline hydroxide to aqueous lactic acid or propionic acid solutions with stirring. From ChLa and ChPro, water was removed using a rotational evaporator (Heidolph Laborota 4003 control, Germany) under the temperature of 343.15 K to minimize moisture.¹² Figure 1 shows the steps for the synthesis of the IL ChLa.

ILs recovery method

Due to the high cost of the ILs and the need to spend a lot of money to provide them, the process of purification and recovery of the ILs and their reuse in later processes were used without losing their original quality. For this purpose, because drugs have very low solubility in water, the solution containing IL + drug is diluted with water to separate and dissolve the drug dissolved in ILs from the mixtures. The residue is removed with a filter paper, and the solution containing IL + water is placed by rotary (Heidolph Laborota 4003 control, Germany) at 70 ° C to evaporate the excess water; the remaining IL is washed with solvents such as ethyl acetate or acetonitrile to purify. The drug separated by the filter paper is rinsed with water. Then the precipitated drug is separated again by the filter paper and dried at room temperature.

Solubility measurement

Solubility is an important topic that has been the subject of much research for several years.^{13,14} In this research

work, the saturation shake-flask method¹⁵ has been used to measure the solubility of drugs in the solvent mixtures. For this purpose, solutions with a known weight fraction of 0.00 to 0.15 ILs were prepared. The mixtures with specific amounts of pure solvents (water, IL) were made. Then, a large amount of drug was added to the solvents in glass vials under permanent stirring in a system with a thermostat (ED, Julabo Co., Germany $T = \pm 0.1 \text{ K}$). Preliminary tests show that to measure the solubility of the drug, the time required to balance in the system is 72h. Then the supernatant solutions were filtered through a 0.45 μm membrane (Durapore[®] membrane filters, type




Figure 2. UV-Vis spectra of (ILs + water) and samples (PXM and LTG + water + ILs).

HV, 0.45 μm , Millipore, MA). Drug uptake in diluted samples (using water/ethanol solutions with 20/80 volume fraction) was measured by UV-Vis spectrophotometer (BiotechUltraspec 2000, England) for LTG at 309 nm and PXM at 251 nm. As shown in Figure 2, the drugs studied (LTG and PXM) in the presence of choline lactate and choline propionate did not change much in their λ_{Max} .

Thermodynamic modeling

Recently, models for the solubility of drugs in water + co-solvent mixtures have been proposed to correlate or predict experimental studies. This research aims to increase the solubility of LTG and PXM in pharmaceutical and industrial studies. The co-solvency models include three types of models, theoretical¹⁶, semi-empirical¹⁷, and empirical.¹⁸ A series of the proper models for the correlation of experimental solubility in solvent mixtures at different temperatures are presented: Apelblat¹⁹, λh ²⁰, Wilson²¹, and e-NRTL²² models, which provide excellent and suitable correlations for LTG and PXM in aqueous ILs solutions. The general characteristics of the applied models are described as follows:

Modified Apelblat equation

The modified Apelblat equation is, known as a semi-empirical model, has three parameters. This study used this model to fit the experimental solubility data. According to this model, the solubility of the drug can potentially change by variations in temperature, and Eq. (1) shows this:

$$\ln x_1 = A + \frac{B}{T} + C \ln T \quad \text{Eq. (1)}$$








where A , B , and C are empirical constants. The values of A and B represent the variation of the activity coefficient of the solution components, and the C value reveals the temperature impact on fusion enthalpy.

λh (Buchowski) equation

The solubility behavior of a solid components in liquid solvents as the Buchowski equation. This equation provided a reasonable explanation for many solid-liquid systems using two adjustable parameters, λ , and h , as reported in previous studies.²³⁻²⁵ This equation can be written as:

$$\ln(1 + \lambda \frac{1-x_1}{x_1}) = \lambda h (\frac{1}{T} - \frac{1}{T_{m1}}) \quad \text{Eq. (2)}$$

Table 1. Explanation of the materials used in this research work.

Chemical name	Source	Mass fraction (purity)	chemical formula	Structure
Lamotrigine	Zahravi	>0.98	$\text{C}_9\text{H}_7\text{Cl}_2\text{N}_5$	
Piroxicam	Zahravi	>0.98	$\text{C}_{15}\text{H}_{13}\text{N}_3\text{O}_4\text{S}_1$	
Choline Chloride	Dae Jung	>0.98	$\text{C}_5\text{H}_{14}\text{ClNO}$	
Lactic acid	Merck	>0.99	$\text{C}_3\text{H}_6\text{O}_3$	
Propionic acid	Merck	>0.99	$\text{CH}_3\text{CH}_2\text{CO}_2\text{H}$	
Potassium hydroxide	Merck	>0.98	KOH	K^+OH^-
Ethyl acetate	Merck	>0.995	$\text{C}_4\text{H}_8\text{O}_2$	
Methanol	Merck	≥ 0.98	CH_4O	

where λ and h are two parameters and T_{m1} is the melting temperature of drugs. The value of λ is recognized as the approximate mean association number of solute molecules, which shows the non-ideality of the solution system, and h estimates the excess mixing enthalpy of solution.

Local composition models

The following equation is used to express a solid-liquid equilibrium (SLE) framework:²⁶

$$-\ln x_1 = \frac{\Delta_{fus}H}{R} \left(\frac{1}{T} - \frac{1}{T_{fus}} \right) + \ln \gamma_1 \quad \text{Eq. (3)}$$

where T_{fus} , $\Delta_{fus}H$, T , x_1 and γ_1 are: fusion temperature and enthalpy for the pure drug, the experimental temperature, equilibrium mole fraction, and the activity coefficient of the drug in the saturated solutions, respectively. Moreover, the fusion enthalpy appears to be temperature independent. To correlate the solubility data of the present drug, the molar excess Gibbs energy, G^{ex} , is identified as the sum of two contributions to generalize the e-NRTL and Wilson for a multi-component aqueous solution containing electrolytes,

$$\frac{G^{ex*}}{RT} = \frac{G^{ex*,LR}}{RT} + \frac{G^{ex*,SR}}{RT} \quad \text{Eq. (4)}$$

where superscript $*$, LR , and SR , represent the asymmetric convention, long-range and short-range interactions, respectively. The extended version of the Pitzer-Debye-Hückel model, $G^{ex*,PDH}$, proposed by Pitzer²⁷ can be used for the long-range contribution term. Also, in this study, the activity coefficient models e-NRTL²⁸ and Wilson²¹ were applied for representing short-range interactions, G^{ex*SR} .

The Pitzer-Debye-Hückel (PDH) equation

The PDH equation for excess Gibbs energy, G^{ex*LR} , can be written as:²⁷

$$\frac{G^{ex*,PDH}}{RT} = -\sum_j x_j \left(\frac{1000}{M_s} \right)^{1/2} \frac{4A_\phi I_x}{\rho} \ln(1 + \rho I_x^{0.5}) \quad \text{Eq. (5)}$$

where M_s is the molar mass of the solvent. The parameter ρ in Eq. (5) is related to the closest approach parameter of ions in solution. The value of $\rho = 14.9$ has been commonly applied for aqueous electrolyte solutions.²⁸ I_x is the ionic strength on a mole fraction basis ($I_x = 0.5 \sum x_i Z_i^2$), Z is the charge number of ions in the solution, x is the mole fraction of ions, and A_ϕ signifies the usual Debye-Huckel parameter for the osmotic coefficient, which is stated by:

$$A_\phi = \frac{1}{3} \left(\frac{2\pi N_A}{V_s} \right)^{1/2} \left(\frac{e^2}{4\pi\epsilon D_s kT} \right)^{3/2} \quad \text{Eq. (6)}$$

V_s is the molar volume, N_A is Avogadro's number, e is the charge of an electron, ϵ is the average dielectric constant of the solvent, k is the Boltzmann constant, and T is the temperature in Kelvin.

Electrolyte-NRTL model

In thermodynamics, commonly considered models are based on activity coefficient for industrial systems such as the electrolyte-NRTL model (e-NRTL) introduced by Chen²⁹ and Chen and Evans.³⁰ For each component, the activity coefficient is defined as the sum of the NRTL and the PDH contributions.²⁹

$$\ln(\gamma_i^*) = \ln(\gamma_i^{*PDH}) + \ln(\gamma_i^{*NRTL}) \quad \text{Eq. (7)}$$

Wilson model

A non-linear model, known as the Wilson model, represents the solubility values of drugs in the binary solvents at experimental temperatures. The equation for this model in a solution with n -component was shown in terms of the activity coefficient as:²¹

$$\ln \gamma_i = 1 - \ln \left[\sum_{j=1}^n x_j \Lambda_{ij} \right] - \sum_{k=1}^n \left[\frac{x_k \Lambda_{ki}}{\sum_{j=1}^n x_j \Lambda_{kj}} \right] \quad \text{Eq. (8)}$$

where Λ_{ij} is the interaction parameters between two components, which is related to the molar volumes of the pure components, λ and characteristic energy, λ differences by:

$$\Lambda_{ij} = \frac{v_j}{v_i} \exp \left(-\frac{\lambda_{ij} - \lambda_{ii}}{RT} \right) \quad \text{Eq. (9)}$$

Interaction parameters were determined by minimizing the value of the objective function as:

$$OF = \sum_{i=1}^n (\ln \gamma_i^{\text{exp}} - \ln \gamma_i^{\text{cal}})^2 \quad \text{Eq. (10)}$$

where n is the experimental points and expresses the experimental and calculated activity coefficients.

To evaluate the goodness of fit between the experimental and correlated solubility data, the average relative deviation percent (ARD%) is used. This parameter for comparison of the models can be calculated using the following equation:

$$\%ARD = 100 \left(\frac{\sum_{i=1}^N \frac{|x_i^{\text{exp}} - x_i^{\text{cal}}|}{|x_i^{\text{exp}}|}}{N} \right) \quad \text{Eq. (11)}$$

where x_i^{exp} , x_i^{cal} and N are experimental and calculated solubility mole fraction and the total number of experimental measurements, respectively.

Results and Discussion

Results obtained from solubility

The mole fraction solubility of LTG or PXM (x_1) in the two solvent mixtures (IL (2) + water (3)) are obtained with Eq. (12):

$$x_1 = \frac{\frac{w_1}{M_1}}{\frac{w_1}{M_1} + \frac{w_2}{M_2} + \frac{w_3}{M_3}} \quad \text{Eq. (12)}$$

where M_i and w_i are the molar mass and weight fractions of i component in the saturated solution, respectively.²³ Tables 2 and 3 show the experimental data obtained from the LTG and PXM solubility in the (water + ILs) mixtures with different concentrations of ILs at various temperatures ($T=298.15$ to 313.15) K. According to the results, it was found that with increasing ILs concentration and with increasing temperature, the solubility of both drugs increases. The results showed that because the heat dissolution process according to the principle of Le Chatelier's equilibrium proceeds towards dissolution and with increasing temperature the dissolution rate increases and because there are strong interactions between the drug and co-solvent help with increasing IL concentration the solubility of drugs increases significantly.

The solubility of LTG and PXM in the aqueous solutions of ILs at different temperatures is given in Figures 3 and 4. The solubility in the presence of ChPro increased more than in ChLa because it was observed that with an increased molecular mass of anion, the solubility in that IL decreased. The molar mass of ChLa is larger than the molar mass of ChPr,o and ChLa has a lower pH than ChPro, i.e. it is more acidic. As a result, ChLa exhibits fewer tendencies than ChPro to take LTG and PXM. Therefore, the solubility of LTG and PXM in ChPro increased more than ChLa, $[\text{ChLa}] < [\text{ChPrO}]$. On the other hand, due to the acidic nature of these ILs, certain interactions that could be van der Waal's type or hydrogen bonding can appear. It also appears that such interactions increase as concentrations of ILs in solution increase, which is evident from the greater solubilization of the drugs.³¹ The solubility improvement in the presence of applied ILs could be due to solute-solvent interactions. The interactions can be divided into H-bonds, van der Waals forces, ion-dipole and dipole-dipole between solute-solvent. They can cause the solubilization of hydrophobic drugs in a solvent.^{24,25} At the atomic scale, drugs (LTG and PXM) molecules and ILs can interact with each other generally through H-bonds and strong ion-dipole interactions. In addition, the more benzene rings in the drugs cause polarity to decrease as a result the higher the solubility, and these results are well consistent with the experimental results. The LTG has less benzene ring rather than PXM; this is why LTG is more soluble

Table 2. Experimental (x_1^{exp})^a and calculated (x_1^{cal}) solubility of LTG in the aqueous IL solutions at different temperatures (T)^b and weight fractions of IL (w_3)^c from Apelblat and λh models.

T / K	Apelblat equation			λh equation	
	$10^5 x_1^{\text{exp}}$	$10^5 x_1^{\text{cal}}$	$100 \frac{x_1^{\text{exp}} - x_1^{\text{cal}}}{x_1^{\text{exp}}}$	$10^5 x_1^{\text{cal}}$	$100 \frac{x_1^{\text{exp}} - x_1^{\text{cal}}}{x_1^{\text{exp}}}$
LTG (1) + ChLa (2) + water (3)					
$w_2=0.000$					
298.15	1.06	1.07	-1.28	1.03	2.71
303.15	1.47	1.41	3.83	1.33	9.62
308.15	1.67	1.74	-4.08	1.70	-1.61
313.15	2.04	2.01	1.35	2.15	-5.61
$w_2=0.020$					
298.15	1.38	1.39	-0.28	1.12	18.86
303.15	1.75	1.74	0.85	1.60	8.85
308.15	2.15	2.17	-0.88	2.25	-4.57
313.15	2.70	2.70	0.29	3.13	-15.77
$w_2=0.050$					
298.15	1.54	1.59	-3.38	1.80	-16.91
303.15	2.63	2.38	9.70	2.34	10.95
308.15	3.04	3.38	-10.99	3.03	0.33
313.15	4.72	4.56	3.49	3.89	17.57
$w_2=0.070$					
298.15	1.85	1.91	-2.86	2.07	-11.61
303.15	2.90	2.66	8.29	2.68	7.26
308.15	3.40	3.72	-9.25	3.45	-1.48
313.15	5.40	5.24	2.96	4.41	18.43
$w_2=0.100$					

Table 2. Continued

298.15	2.08	2.09	-0.16	2.80	-34.71
303.15	3.56	3.54	0.49	3.58	-0.70
308.15	5.04	5.06	-0.50	4.54	9.86
313.15	6.18	6.17	0.17	5.71	7.67
$w_2=0.150$					
298.15	3.29	3.24	1.75	3.30	-0.08
303.15	4.04	4.26	-5.59	4.18	-3.34
308.15	6.03	5.70	5.41	5.25	12.97
313.15	7.59	7.74	-1.91	6.55	13.73
LTG (1) + ChPro (2) + water (3)					
$w_2=0.000$					
298.15	1.06	1.07	-1.28	1.03	2.71
303.15	1.48	1.41	3.83	1.33	9.62
308.15	1.67	1.74	-4.08	1.70	-1.61
313.15	2.04	2.01	1.35	2.15	-5.61
$w_2=0.020$					
298.15	1.61	1.61	-0.24	1.49	7.43
303.15	2.00	1.99	0.75	1.92	4.18
308.15	2.43	2.45	-0.77	2.46	-1.13
313.15	3.03	3.02	0.26	3.13	-3.32
$w_2=0.050$					
298.15	1.71	1.77	-3.32	2.29	-33.77
303.15	3.03	2.74	9.54	2.89	4.55
308.15	3.49	3.87	-10.79	3.63	-3.86
313.15	5.18	5.00	3.43	4.52	12.81
$w_2=0.070$					
298.15	2.20	2.26	-2.92	2.42	-10.14
303.15	3.39	3.11	8.47	3.12	8.14
308.15	3.88	4.24	-9.47	3.98	-2.64
313.15	5.95	5.77	3.03	5.04	15.31
$w_2=0.100$					
298.15	2.96	2.22	-0.79	3.26	-10.14
303.15	4.08	3.98	2.39	4.13	-1.27
308.15	5.61	5.75	-2.50	5.20	7.32
313.15	6.83	6.78	0.84	6.49	5.01
$w_2=0.150$					
298.15	4.65	4.73	-1.8	5.18	-11.45
303.15	6.36	6.02	5.35	6.41	-0.81
308.15	8.14	8.60	-5.78	7.88	3.18
313.15	13.99	13.72	1.89	16.15	-15.44

Table 3. Experimental (x_1^{exp})^a and calculated (x_1^{cal}) solubility of PXM in the aqueous IL solutions at different temperatures (T)^b and weight fractions of IL (w_2)^c from Apelblat and λh models.

T / K	Apelblat equation			λh equation	
	$10^7 x_1^{\text{exp}}$	$10^7 x_1^{\text{cal}}$	$100 \frac{x_1^{\text{exp}} - x_1^{\text{cal}}}{x_1^{\text{exp}}}$	$10^7 x_1^{\text{cal}}$	$100 \frac{x_1^{\text{exp}} - x_1^{\text{cal}}}{x_1^{\text{exp}}}$
PXM (1) + ChLa (2) + water (3)					
$w_2=0.000$					
298.15	4.50	4.29	4.76	4.53	-0.65
303.15	7.15	8.30	-16.15	7.10	0.66
308.15	17.73	15.21	14.19	10.98	38.05
313.15	25.8	26.42	-5.35	16.75	33.23
$w_2=0.020$					
298.15	31.25	31.76	-1.62	42.87	-37.18
303.15	53.99	51.40	4.82	53.78	0.38
308.15	67.71	71.21	-5.18	66.93	1.16

Table 3. Continued.

313.15	86.75	85.28	1.71	82.64	4.74
$w_2=0.050$					
298.15	43.22	43.74	-1.23	49.57	-14.68
303.15	66.40	63.99	3.67	61.99	6.64
308.15	80.63	83.79	-3.90	76.97	4.54
313.15	100.23	98.9	1.29	94.92	5.30
$w_2=0.070$					
298.15	64.52	64.05	0.74	62.51	3.12
303.15	75.23	76.93	-2.31	77.37	-2.85
308.15	97.53	95.27	2.31	95.11	2.48
313.15	120.39	121.39	-0.80	116.15	3.52
$w_2=0.100$					
298.15	71.37	71.49	-0.15	75.25	-5.44
303.15	96.07	95.64	0.45	92.38	3.84
308.15	118.08	118.59	-0.46	112.66	4.59
313.15	137.13	136.94	0.16	136.52	0.45
$w_2=0.150$					
298.15	98.11	98.78	-0.68	105.09	-7.12
303.15	124.82	122.25	2.08	127.10	-1.83
308.15	148.90	152.10	-2.17	152.79	-2.60
313.15	191.63	190.15	0.73	182.58	4.72
PXM (1) + ChPro (2) + water (3)					
$w_2=0.000$					
298.15	4.50	4.29	4.76	4.53	-0.65
303.15	7.15	8.30	-16.15	7.10	0.66
308.15	17.73	15.21	14.19	10.98	38.05
313.15	25.08	26.42	-5.35	16.75	33.23
$w_2=0.020$					
298.15	50.86	51.47	-1.19	58.73	-15.47
303.15	75.85	73.17	3.57	72.58	4.30
308.15	89.39	92.78	-3.78	89.00	0.43
313.15	106.98	105.68	1.26	108.32	-1.26
$w_2=0.050$					
298.15	82.58	84.07	-1.77	104.12	-26.09
303.15	131.07	124.24	5.25	125.98	3.88
308.15	148.9	157.30	-5.66	151.50	-1.74
313.15	175.56	172.32	1.86	181.11	-3.16
$w_2=0.070$					
298.15	118.50	120.73	-1.86	117.47	0.87
303.15	147.83	139.71	5.50	141.37	4.37
308.15	155.16	164.33	-5.95	169.12	-8.99
313.15	200.25	196.25	1.95	201.16	-0.45
$w_2=0.100$					
298.15	135.85	136.64	-0.63	141.42	-4.10
303.15	163.83	160.76	1.90	168.79	-3.03
308.15	192.05	195.92	-1.98	200.31	-4.30
313.15	248.50	246.76	0.67	236.42	4.86
$w_2=0.150$					
298.15	175.60	176.36	-0.46	186.80	-6.38
303.15	212.49	209.54	1.41	220.21	-3.63
308.15	247.71	251.29	-1.46	258.22	-4.24
313.15	305.56	304.04	0.49	301.24	1.41

in water than PXM. The solvating power of ILs is much higher than that of pure water, because, there are H-bonds and dipole-dipole interactions in the water + drug system. Finally, to demonstrate the high accuracy of the LTG and PXM experimental data which have been measured in this

study, the LTG mole fraction solubility in neat water was compared with data of literature which is 1.30×10^{-5} and 7.26×10^{-5} at 298.15 K and 313.15 K, respectively. Also, the experimental data were reported in Table 2, which is 1.315×10^{-5} and 7.340×10^{-5} at 298.15 K and 313.15 K,




Figure 3. Solubility of LTG, x_1 , at a mass fraction of 0.15 of IL at different temperatures.




Figure 4. Solubility of PXM, x_1 , at a mass fraction of 0.15 of IL at different temperatures.

respectively.³² In addition, for PXM solubility in water, the obtained value was 4.499×10^{-7} and 4.1×10^{-7} at 298.15 K in our study and the literature, respectively.³³ The obtained experimental data and the literature values compression demonstrate that the achieved data has a good agreement with some previously reported values (Table 4). On the other hand, there are some reports on the solubility of LTG in systems containing ILs and deep eutectic solvents. In ILs

(choline alaninate, choline bitartrate and choline glycinate) + water co-solvent with a weight fraction of 0.15 for ILs at 298.15 K, the values of 2.987×10^{-5} , 2.629×10^{-5} and 4.750×10^{-5} (mole fraction) has been reported by Shekaari *et al.*³⁴ The value of 3.29×10^{-5} and 4.65×10^{-5} was achieved at the same temperature and weight fraction for LTG solubility in ChLA and ChPro, respectively. These outcomes show an enhancement in the solubility of this drug using these ILs.

Table 4. Comparison between experimental and literature solubility data (mole fraction) of the studied drugs in water.

Solute	T=298.15 K	T=303.15 K	T=308.15 K	T=313.15 K	Ref.
LTG	1.315×10^{-5}	3.133×10^{-5}	4.153×10^{-5}	7.340×10^{-5}	This work
	$1.38 (\pm 0.05) \times 10^{-5}$	$2.52 (\pm 0.06) \times 10^{-5}$	$4.40 (\pm 0.37) \times 10^{-5}$	$8.16 (\pm 0.49) \times 10^{-5}$	³²
	1.33×10^{-5}	3.14×10^{-5}	4.16×10^{-5}	7.31×10^{-5}	³⁵
PXM	4.499×10^{-7}	7.151×10^{-7}	17.730×10^{-7}	25.799×10^{-7}	This work
	4.1×10^{-7}	-	-	-	³⁶

Table 5. Experimental (x_1^{exp})^a and calculated (x_1^{cal}) solubility of LTG in the aqueous ChLa and ChPro solutions at different temperatures (T)^b and weight fractions of IL (w_2)^c from e-NRTL and Wilson models.

T / K	e-NRTL model			Wilson model	
	$10^5 x_1^{\text{exp}}$	$10^5 x_1^{\text{cal}}$	$100 \frac{x_1^{\text{exp}} - x_1^{\text{cal}}}{x_1^{\text{exp}}}$	$10^5 x_1^{\text{cal}}$	$100 \frac{x_1^{\text{exp}} - x_1^{\text{cal}}}{x_1^{\text{exp}}}$
LTG (1) + ChLa (2) + water (3)					
$w_2=0.000$					
298.15	1.06	1.05	0.31	1.06	1.44
303.15	1.47	1.46	0.48	1.47	0.14

Table 5. Continued.

308.15	1.67	1.67	-0.10	1.67	0.05
313.15	2.04	2.05	-0.55	2.04	-0.34
$w_2=0.200$					
298.15	4.36	4.25	2.47	4.15	4.78
303.15	6.66	6.46	2.94	6.40	3.83
308.15	8.60	8.79	-2.16	8.40	2.34
313.15	10.98	10.28	6.33	10.52	4.17
$w_2=0.400$					
298.15	7.71	7.84	-1.65	7.28	5.65
303.15	10.59	10.90	-2.89	10.32	2.60
308.15	13.20	12.77	3.29	12.92	2.12
313.15	18.92	20.33	-7.44	18.25	3.55
$w_2=0.600$					
298.15	11.94	12.10	-1.33	11.22	5.98
303.15	18.89	19.14	-1.34	18.62	1.40
308.15	23.82	24.03	-0.86	23.44	1.58
313.15	27.34	26.73	2.24	26.95	1.44
$w_2=0.800$					
298.15	70.03	70.23	-0.27	65.07	7.08
303.15	95.08	95.99	-0.95	92.80	2.40
308.15	113.07	112.15	0.81	112.19	0.78
313.15	160.28	160.05	0.14	157.96	1.44
$w_2=0.900$					
298.15	471.00	466.06	1.04	448.48	4.78
303.15	636.43	626.55	1.55	612.67	0.31
308.15	907.52	887.83	2.16	864.17	4.77
313.15	1420.00	1403.00	1.22	1344.70	5.30
$w_2=1.000$					
298.15	2110.01	2114.71	-0.22	2503.80	-18.66
303.15	2780.02	2790.30	-0.37	2675.51	-0.27
308.15	3650.04	3651.50	-0.04	3443.11	5.66
313.15	4730.02	4739.00	-0.18	4774.00	-0.93
LTG (1) + ChPro (2) + water (3)					
$w_2=0.000$					
298.15	1.057	1.06	-0.08	1.05	0.18
303.15	1.47	1.46	0.31	1.46	0.33
308.15	1.67	1.67	0.14	1.66	0.57
313.15	2.04	2.02	0.93	2.04	0.03
$w_2=0.200$					
298.15	6.05	5.76	4.92	5.80	4.16
303.15	9.63	9.07	5.84	9.18	4.72
308.15	13.88	13.83	0.32	12.91	6.96
313.15	16.86	17.00	-0.84	16.27	3.48
$w_2=0.400$					
298.15	9.97	10.47	-4.96	9.61	3.58
303.15	13.44	14.18	-5.51	13.04	2.98
308.15	16.27	16.30	-0.20	16.05	1.31
313.15	23.06	22.90	0.69	22.49	2.44
$w_2=0.600$					
298.15	16.45	17.13	-4.14	16.11	2.02
303.15	22.44	22.92	-2.10	22.36	0.39
308.15	36.51	37.24	-2.01	36.75	-0.64
313.15	46.23	46.58	-0.75	45.70	1.14
$w_2=0.800$					
298.15	155.22	142.20	8.39	156.03	-0.52
303.15	220.85	213.95	3.12	220.87	-0.01
308.15	242.87	233.61	3.81	246.66	-1.56
313.15	262.77	263.86	-0.41	267.22	-1.69

Table 5. Continued.

$w_2=0.900$					
298.15	817.80	904.16	-10.55	838.23	-2.49
303.15	1050.01	1099.30	-4.69	1076.10	-2.48
308.15	1430.05	1461.90	-2.23	1475.02	-3.14
313.15	1970.00	1993.01	-1.16	1935.10	1.77
$w_2=1.000$					
298.15	5420.00	5442.50	-0.24	4671.20	13.96
303.15	6100.01	6101.70	-0.02	5651.40	7.35
308.15	7310.01	7290.10	0.27	6777.01	7.29
313.15	8230.01	8226.12	0.04	7589.10	7.78

Table 6. Experimental (x_1^{exp})^a and calculated (x_1^{cal}) solubility of PXM in the aqueous ChLa and ChPro solutions at different temperatures (T)^b and weight fractions of IL (w_2)^c from e-NRTL and Wilson models.

T / K	e-NRTL model			Wilson model	
	$10^7 x_1^{exp}$	$10^7 x_1^{cal}$	$100 \frac{x_1^{exp} - x_1^{cal}}{x_1^{exp}}$	$10^7 x_1^{cal}$	$100 \frac{x_1^{exp} - x_1^{cal}}{x_1^{exp}}$
PXM (1)+ ChLa(2) + water (3)					
$w_2=0.000$					
298.15	4.45	4.55	-1.15	4.51	-0.14
303.15	7.15	7.27	-1.63	7.15	-0.05
308.15	17.73	17.69	0.20	17.82	-0.48
313.15	25.08	25.05	0.11	25.12	-0.14
$w_2=0.200$					
298.15	147.12	149.22	-1.42	137.19	6.74
303.15	174.40	182.46	-4.62	168.42	3.43
308.15	195.84	191.40	2.26	182.45	6.83
313.15	234.32	224.85	4.04	224.29	4.28
$w_2=0.400$					
298.15	267.67	271.72	-1.51	270.32	-0.98
303.15	302.77	305.84	-1.01	290.11	4.18
308.15	351.72	351.72	-5.44	376.41	-7.01
313.15	428.77	456.21	-6.40	409.82	4.42
$w_2=0.600$					
298.15	412.45	431.61	-4.64	395.04	4.22
303.15	675.65	599.59	11.25	641.71	5.02
308.15	854.76	815.37	4.60	841.53	1.54
313.15	980.77	950.60	3.07	937.57	4.40
$w_2=0.800$					
298.15	2515.20	2123.80	15.56	2544.90	-1.18
303.15	3423.90	3623.01	-5.80	3274.01	4.37
308.15	4117.70	4180.10	-1.51	4587.50	-11.41
313.15	5450.30	5469.20	-0.34	5366.02	1.54
$w_2=0.900$					
298.15	9239.40	10330.01	-11.80	9193.90	0.49
303.15	32445.01	32530.02	-0.27	29662.01	8.57
308.15	49514.00	49304.01	0.42	41770.12	15.64
313.15	63935.00	63317.90	0.96	56524.06	11.59
$w_2=1.000$					
298.15	92005.01	91127.01	0.95	70348.01	23.53
303.15	10999.90	11087.00	0.11	102140.25	7.98
308.15	137001.01	136819.99	0.13	108740.03	20.62
313.15	154000.02	153740.02	0.17	142579.99	7.41
PXM (1) + ChPro (2) + water (3)					
$w_2=0.000$					
298.15	4.50	4.53	-0.71	4.56	-1.30

Table 6. Continued.

303.15	7.15	7.16	-0.13	7.15	0.03
308.15	17.73	17.72	0.05	17.56	0.97
313.15	25.08	25.05	0.13	25.26	-0.71
$w_2=0.200$					
298.15	375.85	392.08	-4.31	374.76	0.28
303.15	491.91	490.49	0.28	480.59	2.30
308.15	541.74	535.89	1.07	522.07	3.63
313.15	749.64	743.51	0.18	730.81	2.51
$w_2=0.400$					
298.15	932.70	864.63	7.29	844.14	9.49
303.15	1470.00	1489.90	-1.37	1395.60	5.04
308.15	1583.00	1599.40	-0.47	1513.90	4.25
313.15	1803.01	1836.01	-1.81	17220.21	4.60
$w_2=0.600$					
298.15	3141.62	3048.20	2.97	3243.60	-3.24
303.15	3932.00	3833.09	2.51	3722.10	5.33
308.15	4500.06	4463.81	0.80	4294.00	4.55
313.15	5663.00	5757.00	-1.66	53404.01	5.69
$w_2=0.800$					
298.15	27196.99	31291.00	-15.05	25622.02	5.78
303.15	37740.01	39201.10	-3.85	34550.99	8.46
308.15	46661.02	46377.03	0.59	43357.01	7.07
313.15	67749.99	64282.11	5.11	60449.10	10.77
$w_2=0.900$					
298.15	121501.02	111009.99	9.00	110089.66	9.76
303.15	128098.30	125009.94	2.34	121571.01	5.02
308.15	137301.07	137410.01	-0.29	128478.96	6.21
313.15	148399.99	153529.89	-3.73	144661.01	2.25
$w_2=1.000$					
298.15	514501.03	521421.01	-1.24	484251.12	5.97
303.15	576598.99	578439.86	-0.25	526469.98	8.75
308.15	607701.01	607209.12	0.12	566609.10	6.80
313.15	645989.99	644120.32	0.29	585201.35	9.41

According to Barzegar-Jalali *et al.*⁶, the solubility of LTG in (1-hexyl-3-methylimidazolium bromide + water) mixtures at 298.15 K and weight fraction of 0.1 for the IL is 4.4×10^{-5} ; this value is higher than the solubility we measured in the systems containing the investigated ILs.

Data modeling

Tables 2-6 show the fitting results of four models for the solubility of the investigated drugs in neat and binary water + ILs solvent systems. In many studies on the solubility of drugs in different solvents, quasi-experimental models have been used to fit the experimental solubility results. The most important of these models, as mentioned earlier, are the Apelblat, Yalkowsky, and λh equations. In this study, Apelblat and λh models were used to model the solubility of the drugs in aqueous IL solutions and the dilute region. According to the results, it is observed that the efficiency of the Apelblat ($R^2=0.998$) model is better in systems containing LTG and PXM. It can be seen from Tables 5 and 6, and Figure 4 that the Wilson and e-NRTL models correlate the solubility of the drug in a solvent mixture (water + IL) with an acceptable deviation. The experimental data are almost consistent with the computational data.

From Tables 7 and 8, according to the results of modeling

in the dilute and concentrated regions of ILs mass fraction, it is clear that Apelblat, λh , Wilson and e-NRTL models for LTG and PXM in the presence of two ILs, ChLa and ChPro, are in good agreement with the experimental results.

The results show that the %ARD values of the modified Apelblat and e-NRTL models are relatively low, which indicates that they can be used to correlate the solubility data drugs in solvent mixtures. For the solubility data in binary solvent system in full range concentration of the co-solvent, the e-NRTL model is more suitable for data fitting. It can be seen from Figures 3 and 4 that the solubility of LTG and PXM in the binary solvent system increases.

Conclusion

The chief idea of this research was the aqueous lamotrigine, and piroxicam solubility determination in the presence of two choline-based ionic liquids (ChPro and ChLa) in water under ambient pressure and at temperatures 298.15 K to 313.15 K. The obtained results demonstrated that by increasing the co-solvent mass fractions and temperatures, the higher solubility of the LTG and PXM is reached. In addition, some activity coefficient and semi-empirical models were used to fit the experimental solubility data. Their performance was

Table 7. The calculated average relative deviation percent (ARD%) for the solubility of the LTG and PXM in the aqueous IL solutions at several temperatures from Apelblat and λh models.

W_2	ChLa	ChPro	ChLa	ChPro
	ARD% Apelblat		ARD% λh	
LTG (1) + IL (2)+ water (3)				
0.0200	0.57	0.51	9.60	3.20
0.0500	6.90	6.80	9.20	11.00
0.0700	5.80	6.00	7.80	7.20
0.1000	0.33	1.60	10.60	4.80
0.1500	3.70	3.70	6.00	9.30
Average	3.46	3.72	8.64	7.10
PXM (1) + IL (2)+ water (3)				
0.0200	8.70	2.40	8.70	4.30
0.0500	6.20	3.60	6.20	7.00
0.0700	2.40	3.80	2.40	2.90
0.1000	2.90	1.30	2.90	3.30
0.1500	3.30	0.95	3.30	3.10
Average	4.47	2.41	4.70	4.12

Table 8. The calculated average relative deviation percent (ARD%) for the solubility of the LTG and PXM in the aqueous IL solutions at several temperatures from e-NRTL and Wilson models.

T / K	ChLa	ChPro	ChLa	ChPro
	ARD% e-NRTL		ARD% Wilson	
LTG (1) + IL (2)+ water (3)				
298.15	1.00	4.80	2.80	3.80
303.15	1.50	3.10	0.78	2.61
308.15	1.40	1.30	1.06	3.07
313.15	2.60	0.69	1.90	2.62
Average	1.62	2.47	1.63	3.02
PXM (1) + IL (2)+ water (3)				
298.15	5.30	8.10	5.30	5.10
303.15	3.50	9.50	4.80	4.99
308.15	2.10	0.57	9.08	4.80
313.15	2.20	1.90	4.83	5.14
Average	3.27	5.01	6.00	5.01

classified as e-NRTL (3.09%) < Wilson (3.92%) (for full range concentration of co-solvent) and Apelblat (3.52%) < λh (Buchowski) (5.11%) (for the dilute concentration of co-solvent).

The analyses showed that ChPro is an efficient co-solvent to enhance the solubility of these two poorly water-soluble drugs. These procedure collections can be used efficiently for the separation and crystallization of drugs in various fields of pharmaceutical sciences.

Acknowledgments

The authors wish to thank the University of Tabriz for its financial support.

Author Contributions

NB and MM; investigation, HS and MTZM; project administration, NB and MM; data curation, NB and MM; analysis, HS and MTZ; writing-original draft, NB and MM; investigation, HS and MTZM; writing-review and editing. All authors have read and agreed to the published version

of the manuscript.

Conflict of Interest

The authors report no conflicts of interest.

References

- Gholivand MB, Karimian N. Development of piroxicam sensor based on molecular imprinted polymer-modified carbon paste electrode. Mater Sci Eng C. 2011;31(8):1844-51. doi:10.1016/j.msec.2011.08.019Get.
- Zeeb M, Jamil PT, Berenjian A, Ganjali MR, Olyai MRTB. Quantitative analysis of piroxicam using temperature-controlled ionic liquid dispersive liquid phase microextraction followed by stopped-flow injection spectrofluorimetry. DARU J Pharm Sci. 2013;21(1):63. doi:10.1186/2008-2231-21-63.
- Tantishaiyakul V, Kaewnopparat N, Ingkatawornwong S. Properties of solid dispersions of piroxicam in polyvinylpyrrolidone. Int J Pharm. 1999;181(2):143-51.

- doi:10.1016/S0378-5173(99)00070-8.
- Brogden R, Heel R, Speight T, Avery G. Piroxicam. *Drugs*. 1984;28(4):292-323.
 - Blagden N, de Matas M, Gavan PT, York P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. *Adv Drug Deliv Rev*. 2007;59(7):617-30. doi: 10.1016/j.addr.2007.05.011
 - Barzegar-Jalali M, Jouyban A, Shekaari H, Martinez F, Mirheydari SN. The effect of 1-hexyl-3-methylimidazolium bromide ionic liquid as a co-solvent on the aqueous solubility of lamotrigine at $t=(293.2-313.2)$ K. *J Chem Thermodyn*. 2019;133:261-71. doi:10.1016/j.jct.2019.02.013
 - Agostinho DA, Jesus AR, Silva AB, Esperança JM, Paiva A, Duarte AR, et al. Improvement of new dianionic ionic liquids vs monoanionic in solubility of poorly water-soluble drugs. *J Pharm Sci*. 2021;110(6):2489-500. doi:10.1016/j.xphs.2021.01.014
 - Verma C, Obot I, Bahadur I, Sherif E-SM, Ebenso EE. Choline based ionic liquids as sustainable corrosion inhibitors on mild steel surface in acidic medium: Gravimetric, electrochemical, surface morphology, dft and monte carlo simulation studies. *Appl Surf Sci*. 2018;457:134-49. doi:10.1016/j.apsusc.2018.06.035
 - Rengstl D, Fischer V, Kunz W. Low-melting mixtures based on choline ionic liquids. *Phys Chem Chem Phys*. 2014;16(41):22815-22. doi:10.1039/C4CP02860K
 - Santos de Almeida T, Júlio A, Saraiva N, Fernandes AS, Araújo MEM, Baby AR, et al. Choline-versus imidazole-based ionic liquids as functional ingredients in topical delivery systems: Cytotoxicity, solubility, and skin permeation studies. *Drug Dev Ind Pharm*. 2017;43(11):1858-65. doi:10.1080/03639045.2017.1349788
 - Jadhav NR, Bhosale SP, Bhosale SS, Mali SD, Toraskar PB, Kadam TS. Ionic liquids: Formulation avenues, drug delivery and therapeutic updates. *J Drug Deliv Sci Technol*. 2021;65:102694. doi:10.1016/j.jddst.2021.102694
 - Montes S, Azcune I, Cabañero G, Grande H-J, Odriozola I, Labidi J. Functionalization of cellulose nanocrystals in choline lactate ionic liquid. *Materials*. 2016;9(7):499. doi:10.3390/ma9070499
 - Pitzer KS. *Activity coefficients in electrolyte solutions*. Boca Raton: CRC press; 2018.
 - Golgoun S, Mokhtarpour M, Shekaari H. Solubility enhancement of betamethasone, meloxicam and piroxicam by use of choline-based deep eutectic solvents. *Pharm Sci*. 2021;27(1):86-101. doi:10.34172/PS.2020.58
 - Jouyban V, Khoubnasabjafari M, Martinez F, Peña A, Jouyban A. Solubility of drugs in ethyl acetate-ethanol mixtures at various temperatures. *J Drug Deliv Sci Technol*. 2012;22(6):545-7. doi:10.1016/S1773-2247(12)50094-8
 - Acree Jr WE. Mathematical representation of thermodynamic properties: Part 2. Derivation of the combined nearly ideal binary solvent (nibs)/redlich-kister mathematical representation from a two-body and three-body interactional mixing model. *Thermochim Acta*. 1992;198(1):71-9. doi:10.1016/0040-6031(92)85059-5
 - Jouyban-Gharamaleki A. The modified wilson model and predicting drug solubility in water-cosolvent mixtures. *Chem Pharm Bull*. 1998;46(6):1058-61. doi:10.1248/cpb.46.1058
 - Barzegar-Jalali M, Hanaee J. Model for solubility estimation in mixed solvent systems. *Int J Pharm*. 1994;109(3):291-5. doi:10.1016/0378-5173(94)90391-3
 - Apelblat A, Manzurola E. Solubilities of o-acetylsalicylic, 4-aminosalicylic, 3, 5-dinitrosalicylic, and p-toluic acid, and magnesium-dl-aspartate in water from $t=(278$ to $348)$ K. *J Chem Thermodyn*. 1999;31(1):85-91. doi:10.1006/jcht.1998.0424
 - Buchowski H, Ksiazczak A, Pietrzyk S. Solvent activity along a saturation line and solubility of hydrogen-bonding solids. *J Phys Chem*. 1980;84(9):975-9. doi:10.1021/j100446a008
 - Wilson GM. Vapor-liquid equilibrium. XI. A new expression for the excess free energy of mixing. *J Am Chem Soc*. 1964;86(2):127-30. doi:10.1021/ja01056a002
 - Chen CC, Song Y. Generalized electrolyte-nrtl model for mixed-solvent electrolyte systems. *AIChE J*. 2004;50(8):1928-41. doi:10.1002/aic.10151
 - Forte A, Melo CI, Bogel-Lukasik R, Bogel-Lukasik E. A favourable solubility of isoniazid, an antitubercular antibiotic drug, in alternative solvents. *Fluid Phase Equilib*. 2012;318:89-95. doi:10.1016/j.fluid.2012.01.022
 - Li Y, Wang C, Wang W, Eng AYS, Wan M, Fu L, et al. Enhanced chemical immobilization and catalytic conversion of polysulfide intermediates using metallic mo nanoclusters for high-performance li-s batteries. *ACS Nano*. 2019;14(1):1148-57. doi:10.1021/acsnano.9b09135
 - Shah D, Mansurov U, Mjalli FS. Intermolecular interactions and solvation effects of dimethylsulfoxide on type iii deep eutectic solvents. *Phys. Chem. Chem. Phys*. 2019;21(31):17200-8. doi:10.1039/C9CP02368B
 - Prausnitz JM, Lichtenthaler RN, de Azevedo EG. *Molecular thermodynamics of fluid-phase equilibria*. London: Pearson Education; 1998.
 - Pitzer KS. *Electrolytes. From dilute solutions to fused salts*. *J Am Chem Soc*. 1980;102(9):2902-6. doi:10.1021/ja00529a006
 - Simonson JM, Pitzer KS. Thermodynamics of multicomponent, miscible ionic systems: The system lithium nitrate-potassium nitrate-water. *J Phys Chem*. 1986;90(13):3009-13. doi:10.1021/j100404a043
 - Chen CC, Britt HI, Boston J, Evans L. Local composition model for excess gibbs energy of electrolyte systems. Part i: Single solvent, single completely dissociated

- electrolyte systems. *AIChE J.* 1982;28(4):588-96
30. Chen CC, Evans LB. A local composition model for the excess gibbs energy of aqueous electrolyte systems. *AIChE J.* 1986;32(3):444-54. doi:10.1002/aic.690320311
31. Singh S, Parikh T, Sandhu HK, Shah NH, Malick AW, Singhal D, et al. Supersolubilization and amorphization of a model basic drug, haloperidol, by interaction with weak acids. *Pharm Res.* 2013;30(6):1561-73. doi:10.1007/s11095-013-0994-7
32. Rezaei H, Jouyban A, Barzegar-Jalali M, Martinez F, Rahimpour E. Solubility of lamotrigine in 2-propanol+ water mixtures at t=(293.2 to 313.2) k. *J Mol Liq.* 2019;278:592-9. doi:10.1016/j.molliq.2019.01.082
33. Sotomayor RG, Holguín AR, Cristancho DM, Delgado DR, Martínez F. Extended hildebrand solubility approach applied to piroxicam in ethanol+ water mixtures. *J Mol Liq.* 2013;180:34-8. doi:10.1016/j.molliq.2012.12.028
34. Shekaari H, Mokhtarpour M, Nesari P, Khorsandi M, Behboudi MR, Golmohammadi B. Measurement and thermodynamic modeling of lamotrigine solubility in the presence of some choline-based ionic liquids. *J Chem Eng Data.* 2021;66(5):2200-8. doi:10.1021/acs.jced.1c00073
35. Shekaari H, Zafarani-Moattar MT, Mokhtarpour M, Faraji S. Exploring cytotoxicity of some choline-based deep eutectic solvents and their effect on the solubility of lamotrigine in aqueous media. *J Mol Liq.* 2019;283:834-42. doi:10.1016/j.molliq.2019.03.079
36. Sotomayor R, Delgado D, Martínez F. Preferential solvation of naproxen and piroxicam in ethanol+ water mixtures. *Bulg Chem Commun.* 2015;47:571-7.